CRANBURY, NJ -- Solco Healthcare today announced the launch of generic version of Daiichi-Sankyo’s Benicar-HCT®, Olmesartan Medoxomil and Hydrochlorothiazide Tablets, 20mg/12.5mg, 40/12.5mg and 40mg/25mg. Solco received its final approval by the U.S. FDA for its abbreviated New Drug Application (ANDA) via its parent company Prinston Pharmaceutical Inc.
Olmesartan Medoxomil and Hydrochlorothiazide Tablets are indicted for the treatment of hypertension to lower blood pressure, and are not indicated for the initial therapy of hypertension. “As one of fastest growing US generic companies, we are pleased to be the first wave of companies offering a low cost, high quality alternative to patients in the US,” said Hai Wang, President of Solco Healthcare.
According to QuintilesIMS, total market sales for all three strengths combined for the last twelve months ending December 2016 were $780.1 million.